This Medudy course is a video tutorial for physicians on the topic of “Adenocarcinomas of the stomach and the gastroesophageal junction: HER2, PD-L1, MSI, and CLDN18.2 in treatment decision-making.”
In this video, Prof. Dr. Sylvie Lorenzen, a senior physician at the Department of Internal Medicine III at the Klinikum rechts der Isar of the Technical University of Munich, whose clinical practice focuses on gastrointestinal tumors, provides an overview of the current guideline-based treatment of adenocarcinomas of the stomach and the gastroesophageal junction, with a particular focus on biomarker-based treatment decisions.
In the perioperative setting for resectable locally advanced disease, the new standard treatment option—durvalumab in combination with FLOT (D-FLOT)—which has been approved in the EU since March 2026, is based on the results of the MATTERHORN study.
In the first-line palliative care setting, the increasingly biologically targeted stratification of therapy is presented based on the four predictive biomarkers HER2, PD-L1, MSI-H/dMMR, and Claudin-18.2. The presentation covers HER2-targeted first-line therapy based on the ToGA and KEYNOTE-811 studies, PD-1-based combinations in the HER2-negative setting (KEYNOTE-859, CheckMate 649, RATIONALE-305), CLDN18.2-targeted therapy with zolbetuximab (SPOTLIGHT, GLOW), and first-line options in the MSI-H/dMMR setting.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was made possible with the generous support of MSD.
By the end of this course, you will know:
- the current standard perioperative treatment for resectable adenocarcinoma
- The four predictive biomarkers in treatment decisions
- HER2-targeted first-line treatment regimens with and without a PD-1 inhibitor
- biomarker-guided first-line treatment options in the HER2-negative setting
